Blog
About

0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Monoclonal gammopathy of undetermined significance (MHUS) is characterized by the presence of a serum M-protein less than 3 g/dL, less than 10 % clonal plasma cells in the bone marrow, and the absence of myeloma-defining event. Smoldering multiple myeloma (SMM) is an asymptomatic disorder characterized by the presence of ≥3 g/dL serum M-protein and/or 10-60 % bone marrow plasma cell infiltration with no myeloma-defining event. The risk of progression to multiple myeloma (MM) requiring therapy varies greatly for individual patients, but it is uniform and 1 % per year for MGUS, while higher (10 % per year) and not uniform for SMM patients. The definition of MM was recently revisited patients previously labeled as SMM with a very high risk of progression (80-90 % at 2 years) were included in the updated definition of MM requiring therapy. The standard of care is observation for MGUS patients and although this also applies for SMM, a recent randomized trial targeting high-risk SMM showed that early intervention was associated with better progression-free and overall survival. Biomarkers have become an integrated part of diagnostic criteria for MM requiring therapy, as well as clinical risk stratification of patients with SMM. This paper reviews and discusses clinical implications for MGUS and SMM patients.

          Related collections

          Author and article information

          Journal
          Cancer Treat. Res.
          Cancer treatment and research
          Springer Nature America, Inc
          0927-3042
          0927-3042
          October 4 2016
          : 169
          Affiliations
          [1 ] University Hospital of Salamanca/IBSAL, Paseo San Vicente, 58-182, 37007, Salamanca, Spain. mvmateos@usal.es.
          [2 ] Myeloma Service, Memorial Sloan-Kettering Cancer Center, New York, USA.
          Article
          10.1007/978-3-319-40320-5_1
          27696254

          Comments

          Comment on this article